【摘要】 目的评价促红细胞生成素(epoetin alfa,EPO)对接受化疗的肿瘤患者血红蛋白(hemoglobin,Hb)、输血需求以及生存质量(quality of life,QOL)的影响。方法将79例Hb≤12.0g/dL的恶性肿瘤患者随机分为两组:治疗组接受EPO8000U/次,皮下注射,每周3次,持续8周(EPO组);对照组采用最佳支持治疗(best supportive care,BSC)(BSC组)。观察两组化疗期间Hb变化、输血需求、QOL及不良反应情况。结果在整个治疗过程中EPO组的平均Hb水平保持在12.0g/dL以上,而BSC组的Hb下降。EPO组的Hb反应率为53.8%,明显好于BSC组7.5%(P<0.0001)。EPO组和BSC组的输血需求分别为7.7%、30%(χ2=6.388,P<0.05)。8周时,EPO组的FACT-An贫血及乏力平均分数变化分别为(2.16±12.84)、(3.58±10.52),BSC组分别为(-4.43±13.42)、(-5.34±11.14)(P<0.0001)。两组的不良反应相似。结论EPO能使接受化疗的肿瘤患者保持Hb水平、减少输血需求、提高生存质量。更多还原

【Abstract】 Objective To evaluate the effects of epoetin alfa(EPO)therapy on hemoglobin(Hb),transfusion requirements and quality of life(QOL)in patients with cancer receiving chemotherapy.Methods Seventy-nine patients with Hb≤12.0g/dL were randomized to receive EPO 8 000U three times per week s.c(EPO group)or best supportive care(BSC group)for 8 weeks.Hemoglobin responses,transfusion requirements,QOL and toxicity were measured.Results EPO maintained Hb levels throughout the study with mean Hb levels ≥12.0g/dL,compared with a decrease with BSC.Hemoglobin responses were 53.8% for EPO group,significantly higher than that in BSC group(7.5%)(P<0.0001).Transfusion requirements in EPO patients and BSC patients were 7.7% and 30%(χ2=6.388,P<0.05),respectively.At the eighth week,mean change score of FACT-An anemia and fatigue was(2.16±12.84),(3.58±10.52)for EPO group and(-4.43±13.42),(-5.34±11.14)for BSC group(P<0.0001 for both comparisons).Adverse events were similar between the groups.Conclusion EPO maintains hemoglobin level,reduces transfusion requirements and improves QOL in patients with cancer receiving chemotherapy.更多还原